The decision concerns the Autus Size-Adjustable Valve, a surgically implanted pulmonary heart valve intended for pediatric patients with congenital pulmonary valve disease.
At a glance
- The approval: announced by the FDA on October 1, 2026.
- The key feature: the valve’s diameter can be increased after implantation.
- The potential benefit: reducing the need for additional open-heart surgeries, with longer-term data still being collected.
- The regulatory pathway: the device received Premarket Approval following Breakthrough Device designation and participation in the TAP program.
A valve designed to accommodate growth
The Autus Size-Adjustable Valve is a pulmonary valve intended for pediatric patients with congenital pulmonary valve disease.
Initial implantation requires surgery. The valve’s diameter can subsequently be increased using a balloon catheter, from approximately 13 millimeters to 22 millimeters.
The valve does not grow on its own: expansion requires a procedure.
This distinction is central to understanding the device’s innovation. The aim is not to eliminate every subsequent intervention or procedure, but to provide a valve designed to be expanded over time as the child grows.
Another feature concerns the valve leaflets, which are made from polymeric material rather than animal-derived tissue. According to the FDA, this is the first time the agency has approved a valve with polymeric leaflets for any indication.
What clinical data are available?
The approval is based on data from a clinical study involving 62 pediatric patients across 12 U.S. sites.
For the first 60 patients, the FDA reports acceptable hemodynamic performance at the six-month follow-up, with no more than mild leakage back through the valve.
The FDA also reports successful implantation in all study participants, with no deaths, blood clots requiring additional treatment, strokes, or other clot-related complications.
Three patients experienced valve frame fractures, and two had reduced movement of one leaflet, without associated symptoms. In two patients, valve performance began to deteriorate as they started to outgrow the valve. Both valves were successfully expanded without further invasive surgery.
Experience with expansion nevertheless remains limited. Longer-term studies are ongoing to better understand the risks, assess valve function over time, and determine whether expansion can reduce the need for surgical procedures.
The regulatory pathway: what PMA approval means
The device received approval through the Premarket Approval, or PMA, pathway, following Breakthrough Device designation and participation in the TAP program.
PMA is the FDA’s scientific and regulatory review process for assessing the safety and effectiveness of Class III medical devices subject to this pathway.
It is the FDA’s most stringent type of medical device marketing application. Before granting approval, the agency reviews the scientific evidence submitted, including nonclinical and clinical data, to determine whether there is reasonable assurance of safety and effectiveness for the intended use.
The assessment may include laboratory data, biocompatibility, mechanical strength, wear, clinical investigation results, adverse events, and other information relevant to the device’s safety and performance.
Approval therefore rests on an assessment of the evidence submitted, rather than technological novelty alone.
Breakthrough Device designation and TAP: two distinct tools
Breakthrough Device designation is part of a voluntary FDA program intended to accelerate the development, assessment, and review of certain technologies.
The program covers devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions.
Designation facilitates interaction with FDA experts and provides for prioritized review of submissions. However, it does not constitute marketing authorization: the device must still meet the applicable safety and effectiveness standards.
The Total Product Life Cycle Advisory Program, or TAP, is a separate voluntary program designed to facilitate early and frequent communication between developers and the FDA, as well as engagement with other parties involved in technology development and patient access.
According to the FDA, the Autus Size-Adjustable Valve represents the first pediatric approval to emerge from the TAP program.
TAP supports engagement throughout the product life cycle. It remains distinct from the final approval decision, which is made through the applicable regulatory pathway.
Why this development matters
This approval is relevant for three main reasons:
- The first concerns the clinical need: in pediatric patients with congenital pulmonary valve disease, growth can make further procedures or surgeries necessary over time.
- The second concerns device design: a valve that can be expanded after implantation directly addresses the challenge of accommodating a growing patient.
- The third concerns the regulatory process: the decision brings together PMA, Breakthrough Device designation, and TAP participation, illustrating how different FDA tools can contribute at different stages of an innovative device’s development and assessment.
At the same time, the FDA highlights the need for longer-term follow-up data to better understand risks, valve function over time, and the potential impact on reducing surgical procedures.
Official sources
- FDA — FDA Approves First Heart Valve Designed to Grow with Children, October 1, 2026
- FDA — Premarket Approval (PMA)
- FDA — Breakthrough Devices Program
- FDA — Total Product Life Cycle Advisory Program (TAP)
Stay informed with MDN – Medical Device News
MDN is a free weekly newsletter dedicated to regulatory updates on medical devices and IVDs, based on official and institutional sources.
Subscribers receive it by email every Monday, one week before publication on the website.
Subscribe to MDN – Medical Device News.
Did you find this insight useful?
If you found this insight useful, you can share it with other professionals in the sector.
More articles
Informational note
This article is for informational purposes only and does not constitute medical, regulatory, legal, technical, or professional advice. Please refer to current official documentation for the applicable indications for use, requirements, and conditions. Clinical decisions are the responsibility of healthcare professionals.